Immuron Ltd
IMC
Company Profile
Business description
Immuron Ltd is a commercial and clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.
Contact
Chapman Street
Unit 10, 25-37
Blackburn North
MelbourneVIC3130
AUST: +61 398245254
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2025
Employees
7
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,786.70 | 13.10 | 0.15% |
| CAC 40 | 7,557.31 | 0.85 | -0.01% |
| DAX 40 | 23,649.30 | 150.97 | 0.64% |
| Dow JONES (US) | 43,386.84 | 404.41 | 0.94% |
| FTSE 100 | 8,735.60 | 16.85 | 0.19% |
| HKSE | 24,357.21 | 31.81 | 0.13% |
| NASDAQ | 20,167.91 | 194.36 | 0.97% |
| Nikkei 225 | 40,215.36 | 630.78 | 1.59% |
| NZX 50 Index | 12,544.91 | 64.86 | 0.52% |
| S&P 500 | 6,141.02 | 48.86 | 0.80% |
| S&P/ASX 200 | 8,556.80 | 6.00 | 0.07% |
| SSE Composite Index | 3,443.62 | 4.83 | -0.14% |